Spontaneous haemorrhagic cholecystitis secondary to the use of novel anticoagulants (rivaroxaban)
Affiliation
Royal Wolverhampton NHS Trust; The Dudley Group NHS Foundation Trust.Publication date
2023-11-06Subject
Gastroenterology
Metadata
Show full item recordAbstract
Haemorrhagic cholecystitis is a rare complication of acute cholecystitis. It carries a high risk of morbidity and mortality. Risk factors for haemorrhagic cholecystitis include cholelithiasis, trauma, malignancy and the use of anticoagulants. There have only been a few reported cases of haemorrhagic cholecystitis secondary to the use of novel oral anticoagulants (NOACs). The demographic transition of an ageing population will potentially increase the utilisation of NOACs. Therefore, the incidence of haemorrhagic cholecystitis secondary to NOACs will likely increase. Awareness and prompt diagnosis is paramount to avoid morbidity and mortality associated with haemorrhagic cholecystitis.Citation
Kurian M, Lim CK, Kler P, Chow BL, Chacko CJ. Spontaneous haemorrhagic cholecystitis secondary to the use of novel anticoagulants (rivaroxaban). BJR Case Rep. 2023 Jan 11;9(6):20220128. doi: 10.1259/bjrcr.20220128. PMID: 37928697; PMCID: PMC10621570.PMID
37928697Publisher
British Institute of Radiologyae974a485f413a2113503eed53cd6c53
10.1259/bjrcr.20220128